Comparing this to SRX is just plain wrong. And your statements about SRX relying on a supplementary use of their technology is INCORRECT.
To assist you, SRX is making money because they are supplying end of the line therapy. The latest announcement just means that the treatment is not suitable for first line therapy. Their technology has never been for a supplementary use, as all their revenue is derived from the primary use as end of line therapy.
If you need to ask what the above means, then you dont know enough, and should not comment on something you are ignorant on.
MSB Price at posting:
$3.88 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)